is sufficient to prevent anergy in a model of APC-induced T cell anergy. However, studies using anti-TCR antibody-induced anergy showed that the ability of ERKs to reverse T cell anergy is dependent on the anergic model utilized.
INTRODUCTION
The MAP kinase cascade governs multiple cellular processes in T cell function, including proliferation and differentiation. Activation of the MAP kinase ERK (extracellular signal-regulated kinase) is required for IL-2 gene transcription and T cell proliferation via engagement of the T cell receptor (TCR) (1) . In addition, the magnitude of ERK activation may regulate the response of T cells to TCR engagement (2,3). Therefore, it is expected that both the magnitude and duration of ERK activation is tightly regulated in T cells.
One potential mechanism of ERK regulation is the modulation of Ras signaling by the small G protein, Rap1. Rap1, a member of the Ras super-family, was identified as an antagonist of Ras dependent transformation in fibroblasts (4) . In many cell types, including T cells, Rap1 has been shown to inhibit ERK activation by blocking Rasdependent activation of the MAP kinase kinase kinase, Raf-1 (5-8). Rap1 is activated upon TCR engagement in the absence of costimulation (5,9,10) and can limit TCRinduced signals to ERK (5, 11) . Interestingly, Rap1 is inhibited by the engagement of the CD28 costimulatory receptor (10, 12) , suggesting that one of the functions of Rap1 activation may be to limit ERK activation in the absence of costimulation (5) . Indeed, in models of T cell anergy elicited by stimulation through the TCR alone, Rap1 is constitutively active and may limit signaling downstream of Ras (13) . These phosphorylations of Raf-1 do not occur upon recruitment of Raf-1 to Rap1 (19) .
For this reason, Rap1 activity results in ERK activation when B-Raf is expressed, but may prevent Raf-1 activation by sequestering Raf-1 without activating it. Transfection of B-Raf into non-lymphoid cells that do not normally express this Raf isoform has been proposed to allow Rap1 to couple to ERK (17, 20, 21) . Since T cells are not thought to express B-Raf, we tested the hypothesis that the transgenic expression of B-Raf in peripheral T cells might have a similar action.
Recent studies examining the role of ERK inhibition in T cell anergy have utilized constitutively active or interfering mutants of upstream activators of ERKs (22) as well as the pharmacological inhibition of the ERK kinase MEK (23) . These manipulations result in the activation or inhibition of ERK without mirroring physiological levels of regulation (24) (25) (26) . By introducing B-Raf into T cells, we hoped to test the hypothesis that B-Raf expression can permit Rap1 to couple positively to ERKs. By selectively enhancing ERK signaling through Rap1 without altering ERK activation through Ras, ectopic B-Raf expression in T cells might provide the opportunity to examine the consequence of enhancing ERK selectively in the absence of costimulation.
We show that B-Raf expression in T cells converted Rap1 into an activator of ERKs. Additionally, B-Raf-expressing T cells proliferated in the absence of costimulation. Moreover, these cells could not be anergized by APCs expressing low levels of B7, which were deficient in providing costimulation. University, MO). This construct was used to generate transgenic mouse lines in C57BL6/J mice by standard procedures. Potential founders were genotyped using both tail and ear DNA by Southern blot using random-primed probes derived from the fulllength cDNA and by PCR analysis using vector specific primers. The founders that were identified by these methods were mated with wild type C57BL6/J mice and F1 litters genotyped by PCR. Three lines were established and shown to have the same phenotype.
One B-Raf-expressing line was chosen to cross to the AD10 TCR transgenic line.
Experiments were performed on adult mice, except for thymocyte staining which was performed on thymocytes from 3 week-old mice. For anergy experiments B-Raf transgenic animals were crossed with the TCR transgenic mouse line, AD10 (29) . T cells from the AD10 TCR transgenic mice express a recombined TCR, which recognizes pigeon cytochrome c (PCC) peptide (amino acids 88-104) or moth cytochrome c (MCC) peptide (amino acids 88-103) presented by MHC class II I-E k . B-Raf transgenic mice were also crossed with the TCR transgenic mouse line, AND, which also recognizes the PCC and MCC peptides presented by I-E k (29) . In all animal studies, experiments were performed in compliance with the relevant laws and institutional guidelines and were approved by the IACUC. To initiate anergy via antibody stimulation, viable cells were recovered over a density gradient and 5x10 6 cells/ml were incubated overnight with plate bound anti-TCRβ antibody (10 µg/ml, H57-957, Pharmingen) or isotype control. T cells were removed from the plates and rested for 24h prior to experimental use. For experiments using PD98059 (Sigma, St. Louis, MO), the drug was applied at 20 µM during the initial 24 hour incubation with fibroblast APCs. 
Raf-1 and B-Raf kinase Assays--

Preparation of Nuclear Extracts--Control and anti-TCR treated T cells (2.5x10
Western Blot--Cells were lysed in ice-cold Rap1 lysis buffer with inhibitors and the protein content of lysates determined by BioRad assay as described above (5).
Proteins were separated in a 10-12% gel, followed by transfer to a polyvinylidine difluoride membrane. Membranes were blocked in 5% BSA and probed with either anti- Levels of c-fos were detected from 4 µg of total nuclear proteins by Western blot using anti-c-fos antibody (H-125, Santa Cruz Biotechnology Inc., Santa Cruz, CA).
CD69 Expression--Anergic and non-anergic AD10 and AD10xB-Raf T cells (10 6 cells/ml) were stimulated with 2 µg/ml anti-CD3 and 10 µg/ml anti-CD28 plate bound Abs (Pharmingen, San Diego) for 18h at 37°C. Cells were harvested on ice and stained for CD69 expression with biotinylated anti-CD69 mAb (H1.2F3, PharMingen) followed by streptavidin APC (see Flow Cytometry). proposed that Rap1 is a potent activator of ERKs in B-Raf-expressing cells (8, 17) . To test whether a constitutively active mutant of Rap1 (RapV12), could augment ERK signaling in T cells transfected with B-Raf, we used a transcription-coupled assay monitoring the ERK-dependent phosphorylation of the transcription factor Elk-1 (17, 33) .
T Cell Proliferation Assay--Naïve
The data show that neither B-Raf nor RapV12 activated Elk-1 when transfected alone.
However, when transfected together, B-Raf and RapV12 co-operated to activate Elk-1 dependent transcription. This action of B-Raf was specific for this isoform of the Raf family kinases, as co-transfection of Raf-1 with RapV12 did not enhance Elk-1 activity (Fig. 1A) . To examine if the introduction of B-Raf had an effect on T cell development, we examined thymocyte development in AD10 TCR transgenic and AD10xB-Raf animals by examining CD4 and CD8 expression. The AD10 TCR is specific for pigeon or moth cytochrome c (PCC or MCC) presented on I-E k . No differences were seen in positive selection of T cells into the CD4 compartment (Fig. 1D) . Similarly, there were no 14 differences in thymocyte development when B-Raf-expressing mice were crossed with AND TCR transgenic mice (Fig. 1D) , whose TCR shares specificity with the AD10 TCR. (Fig. 2B) .
The B-Raf Transgene is Expressed in Transgenic but not Wild
Transgenic Expression of B-Raf Enhances the Proliferation and ERK
In isolated B-Raf-expressing splenic T cells, CD3 ligation alone caused a larger increase in the activity of ERK1 and ERK2 compared to wild type cells.
We also examined the effect of B-Raf on the ability of costimulation via CD28 ligation to augment ERK activation. In wild type cells, costimulation enhanced the magnitude of ERK activation (Fig. 2B) . Interestingly, in the B-Raf-expressing cells, coligation of CD3 and CD28 did not lead to enhanced ERK activation. Rather, it inhibited ERK activation to below the levels seen by CD3 ligation alone (Fig. 2B) , suggesting that the increased ERK activation seen in CD3-stimulated B-Raf-expressing cells could be inhibited by CD28 costimulation. The pattern of ERK activation in wild type and B-Rafexpressing T cells reflects the activity of the Raf kinase isoforms. Endogenous Raf-1, which is expressed to similar levels in both wild type and transgenic T cells, showed increased activation under conditions of costimulation in both cell types (Fig. 2C) . In contrast, the activity of B-Raf (expressed only in transgenic T cells) was greater in the absence of costimulation (Fig. 2C) . Under conditions of costimulation, Raf-1 activity was increased while B-Raf activity was decreased. 
B-Raf-expressing T Cells Proliferate in Response to B7 lo
APCs. Although antibody stimulation of the TCR has been widely used to recreate TCR signaling, the use of APCs expressing either high or low levels of B7 provides a more relevant model to examine the role of costimulatory molecules in antigen-dependent activation (35-37).
We tested the ability of AD10 TCR transgenic and AD10xB-Raf T cells to proliferate in response to fibroblast APCs that expressed either high levels of B7 (B7 hi APCs) or low levels of B7 (B7 lo APCs). B7 hi and B7 lo fibroblasts expressed similar levels of I-E k with an antigenic peptide covalently attached to the β-chain. B7 lo fibroblasts expressed less than 5% of the level of surface B7.1 than B7 hi fibroblasts. B7.2 was undetectable in both lines (Fig. 3A) . Following incubation with B7 hi APCs, both AD10 and AD10xB-Raf T cells proliferated to the same degree, demonstrating that B7 hi APCs provide functional costimulation (Fig. 3B ). Following incubation with B7 lo APCs, AD10 T cells were unable to proliferate, indicating that these APCs were not capable of providing functional costimulation (Fig. 3B) . In contrast, B-Raf-expressing T cells proliferated better in response to B7 lo APCs than in response to B7 hi APCs, although their basal proliferation was the same. These data suggest that B-Raf-expressing T cells are able to be stimulated to proliferate in the absence of functional costimulation (Fig. 3B ).
The absence of costimulation induces T cell anergy characterized by a lack of proliferation, loss of ERK activation, and the absence of IL-2 production in response to subsequent exposure to antigen with costimulation (38, 39) . To examine whether B-Raf expression could overcome anergy, we measured the ability of AD10 and AD10xB-Raf T cells to proliferate in response to restimulation following exposure to B7 hi or B7 lo APCs.
Both AD10 and AD10xB-Raf T cells stimulated with B7 hi APCs were able to proliferate upon restimulation (Fig. 3C ). AD10 T cells previously stimulated with B7 lo APCs were anergic, and unable to proliferate upon restimulation (Fig. 3C ). This block in proliferation could be overcome by the addition of exogenous IL-2 (data not shown). In contrast, AD10xB-Raf cells previously stimulated with B7 lo APCs were able to proliferate upon restimulation, suggesting that B-Raf activation of ERKs was sufficient to prevent anergy induction under conditions of low B7 (Fig. 3C ).
Rap1 is Constitutively Active in T Cells Stimulated with B7 lo Fibroblasts and Correlates with Increased ERK Activation in B-Raf-expressing but not Wild Type T cells.
We examined Rap1 activation in B-Raf-expressing T cells followed the levels of Rap1 activation, and was highest following CD3 stimulation and was reduced by co-stimulation (Fig. 4B, B7 hi ).
Following incubation of AD10xB-Raf T cells with B7 lo APCs, Rap1 and ERKs were constitutively activated, whereas Ras showed no activity (Fig. 4B, low B7 ). These data provide strong evidence that Rap1 is signaling through B-Raf to activate ERKs.
Like ERKs, the stress activated protein kinases [SAP kinases, or c-Jun N-terminal kinases (JNKs)] are activated upon costimulation (40) (41) (42) and are inhibited during anergy (43, 44) ( Fig. 5) . Importantly, B-Raf expression did not affect JNK signaling (Fig. 5) , demonstrating that the absence of JNK activation is not sufficient to induce anergy.
Indeed, B-Raf has only one known action, the activation of MEK and ERKs. Therefore, these data suggest that the activation of ERKs is sufficient to prevent these T cells from becoming anergic. AD10xB-Raf T cells also induced anergy, as these cells did not proliferate (Fig. 6A ). The addition of exogenous IL-2 rescued the proliferation defect of both the AD10 and AD10xB-Raf anergic cells (data not shown), suggesting that these cells were anergic secondary to a deficiency in IL-2 production.
The Expression of B-Raf is Not Sufficient to Rescue Anti-TCR
Rap 1 and ERKs are Constitutively Active in B-Raf-expressing T Cells following
Antibody-induced Anergy. The biochemical effects seen following anergy induction by plate-bound anti-TCR-antibody ( Fig. 6 B-E) mimicked those seen following incubation with APCs (Fig. 4) . Control AD10 T cells responded to subsequent CD3 stimulation by activating ERKs to a modest degree. Costimulation (3 + 28) inhibited Rap1 activation and potentiated ERK activation, without further increasing Ras activation (Fig. 6B ).
Anti-TCR stimulated cells showed biochemical hallmarks of anergy: constitutive activation of Rap1, the absence of Ras activation, and absence of ERK activation under all conditions of restimulation (Fig. 6C ).
Control AD10xB-Raf cells responded to subsequent CD3 stimulation by activating Rap1, Ras, and ERKs robustly. Costimulation (3 + 28) inhibited Rap1 activation, and reduced ERK activation, with no effect on Ras (Fig. 6D) . Anti-TCR stimulated cells showed constitutive activation of Rap1, absence of Ras, and elevated ERK activity, under all conditions of restimulation (Fig. 6E) . These data provide strong evidence that B-Raf expression converted Rap1 into an activator of ERKs. Moreover, these data demonstrate that both models of anergy induction (APC-and antibody- 
ERK Activation in Anergic T cells can Activate Downstream Effectors. To see if
this constitutive ERK activation could couple to downstream targets, we examined the regulation of two T cell gene products whose expression is ERK-dependent; the T cell activation marker CD69 (45) and the transcription factor c-fos (41, 46) . CD69 expression in control AD10 and AD10xB-Raf T cells was enhanced to the same degree following restimulation. In contrast, the expression of CD69 in anti-TCR treated AD10xB-Raf T cells was significantly higher than that seen in anti-TCR treated AD10 T cells (Fig. 7A ).
Protein levels of c-fos were increased following costimulation of control AD10 and AD10xB-Raf T cells, and this increase was lost in anti-TCR treated AD10 T cells. In contrast, in anti-TCR treated AD10xB-Raf T cells levels of c-fos protein expression were much higher (Fig. 7B) . Taken The distinct specificities of Ras and Rap1 for Raf-1 are probably not due to differences in affinity for Raf-1, but rather may be related to the subcellular localization of Ras and Rap1. Ras recruits Raf-1 to specific membrane locales where Raf-1 can be further activated, by phosphorylation, whereas Rap1 fails to do so (19) . The inability of Rap1 to activate Raf-1 can be overcome by activating mutations at these sites of phosphorylation. These activating mutants encode residues that are present in B-Raf and provide an explanation for the specificity of Rap1 for B-Raf versus Raf-1.
We took advantage of this pattern of Rap1 activation to engineer T cells that expressed B-Raf, which allows Rap1 to activate ERKs. Exposure to APCs expressing high or low levels of B7 provided the control and anergizing conditions, respectively. 
